Bio
We haven't found any bio for you yet.
Researcher Links
Loading links...
Publications by Type
Loading publications…
The last 5 uploaded publications
Performance status and quality of life in patients with advanced synovial sarcoma or myxoid/round cell liposarcoma receiving afamitresgene autoleucel
Michael J. Wagner, Colin Lunt, Dejka M. Araujo, Jean Yves Blay, Mihaela Druta, Steven Attia, Claudia Maria Valverde Morales, Kristen N. Ganjoo, Scott M. Schuetze, Sandra P. D’Angelo, Elizabeth T. Loggers, Albiruni Abdul Razak, Édouard Forcade, Sandra J. Strauss, Erin Van Winkle, Peter Bayer, Jane P. F. Bai, D. Bestul, Viral Desai, Murray Yule, Dennis Williams, Elliot Norry, Brian A. Van Tine (2025). Performance status and quality of life in patients with advanced synovial sarcoma or myxoid/round cell liposarcoma receiving afamitresgene autoleucel. , 4, DOI: https://doi.org/10.1016/j.esmorc.2025.100025.
Article19 days agoLong-Term Survival of Patients with Advanced/Metastatic Synovial Sarcoma or Myxoid/Round Cell Liposarcoma Who Received the T-Cell Receptor T-Cell Therapy, Afamitresgene Autoleucel, in the Phase 2 Spearhead-1 Trial
Sandra P. D’Angelo, Mihaela Druta, Brian A. Van Tine, Scott M. Schuetze, Jean Yves Blay, Claudia Maria Valverde Morales, Édouard Forcade, Kristen N. Ganjoo, Axel Le Cesne, Sandra J. Strauss, Dejka M. Araujo, Edwin Choy, Christopher D. Dupont, Dennis Williams, Jane P. F. Bai, Lilliam Fernandes, Erin Van Winkle, Amber K. O’Connor, Elliot Norry (2025). Long-Term Survival of Patients with Advanced/Metastatic Synovial Sarcoma or Myxoid/Round Cell Liposarcoma Who Received the T-Cell Receptor T-Cell Therapy, Afamitresgene Autoleucel, in the Phase 2 Spearhead-1 Trial. , 31(2), DOI: https://doi.org/10.1016/j.jtct.2025.01.380.
Article19 days agoTable S2 from Circulating Tumor Cells and Biomarker Modulation with Olaratumab Monotherapy Followed by Olaratumab plus Doxorubicin: Phase Ib Study in Patients with Soft-Tissue Sarcoma
Javier Martín‐Broto, Antonio López–Pousa, Andrew S. Brohl, Brian A. Van Tine, Benjamin Powers, Silvia Stacchiotti, Jean Yves Blay, James Hu, Gerard J. Oakley, Hong Wang, Anna M. Szpurka, Donna E. Levy, Gary Mo, Matteo Ceccarelli, Robin L. Jones (2023). Table S2 from Circulating Tumor Cells and Biomarker Modulation with Olaratumab Monotherapy Followed by Olaratumab plus Doxorubicin: Phase Ib Study in Patients with Soft-Tissue Sarcoma. , DOI: https://doi.org/10.1158/1535-7163.22521156.
Preprint18 days agoFigure S4 from Circulating Tumor Cells and Biomarker Modulation with Olaratumab Monotherapy Followed by Olaratumab plus Doxorubicin: Phase Ib Study in Patients with Soft-Tissue Sarcoma
Javier Martín‐Broto, Antonio López–Pousa, Andrew S. Brohl, Brian A. Van Tine, Benjamin Powers, Silvia Stacchiotti, Jean Yves Blay, James Hu, Gerard J. Oakley, Hong Wang, Anna M. Szpurka, Donna E. Levy, Gary Mo, Matteo Ceccarelli, Robin L. Jones (2023). Figure S4 from Circulating Tumor Cells and Biomarker Modulation with Olaratumab Monotherapy Followed by Olaratumab plus Doxorubicin: Phase Ib Study in Patients with Soft-Tissue Sarcoma. , DOI: https://doi.org/10.1158/1535-7163.22521162.v1.
Preprint18 days agoTable S1 from Circulating Tumor Cells and Biomarker Modulation with Olaratumab Monotherapy Followed by Olaratumab plus Doxorubicin: Phase Ib Study in Patients with Soft-Tissue Sarcoma
Javier Martín‐Broto, Antonio López–Pousa, Andrew S. Brohl, Brian A. Van Tine, Benjamin Powers, Silvia Stacchiotti, Jean Yves Blay, James Hu, Gerard J. Oakley, Hong Wang, Anna M. Szpurka, Donna E. Levy, Gary Mo, Matteo Ceccarelli, Robin L. Jones (2023). Table S1 from Circulating Tumor Cells and Biomarker Modulation with Olaratumab Monotherapy Followed by Olaratumab plus Doxorubicin: Phase Ib Study in Patients with Soft-Tissue Sarcoma. , DOI: https://doi.org/10.1158/1535-7163.22521159.v1.
Preprint18 days ago